Related Experiment Videos
Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice
Abstract:
Thalidomide's reported ability to inhibit angiogenesis has led to clinical trials determining its effectiveness in combating various types of cancer. This study explored thalidomide's antitumorigenic potential when administered alone and in combination with cisplatin to DBA2/J mice whose tumors were induced by murine erythroleukemic cells. Thalidomide treatment alone produced no significant inhibitory effect on tumor development and metastasis. Mice that received both drugs had significantly lower incidences of both primary and secondary tumors as compared to the untreated control group. Cisplatin, administered alone or in combination with thalidomide, led to a significant delay in tumor formation and a longer life span than was recorded in untreated mice. However, the combination treatment results were not significantly different from those of cisplatin treatment used as a single agent. In in vitro cell multiplication studies using murine erythroleukemic and murine endothelial cells, thalidomide failed to inhibit cell proliferation. However, cisplatin treatment with or without thalidomide, significantly inhibited the multiplication of both cell lines in a dose dependent manner. Thalidomide does not appear to be a beneficial adjuvant to cisplatin treatment.
Insights
Thalidomide did not inhibit tumor growth alone or enhance cisplatin's effect in mice. Cisplatin alone significantly delayed tumor formation and extended lifespan, showing thalidomide is not a beneficial adjuvant.
Area of Science:
- Oncology
- Pharmacology
Background:
- Thalidomide is investigated for anti-cancer properties due to its anti-angiogenic potential.
- Cancer therapy often involves combination treatments to improve efficacy.
Purpose of the Study:
- To evaluate thalidomide's antitumorigenic effects alone and in combination with cisplatin.
- To assess the impact on tumor development, metastasis, and cell proliferation.
Main Methods:
- DBA/2J mice with chemically induced tumors received thalidomide, cisplatin, or combination therapy.
- In vitro studies assessed cell proliferation of cancer and endothelial cells.
Main Results:
- Thalidomide monotherapy showed no significant tumor inhibition.
- Combination therapy with thalidomide and cisplatin reduced tumor incidence compared to controls.
- Cisplatin, alone or combined, significantly delayed tumor formation and prolonged survival.
- Thalidomide did not inhibit cell proliferation in vitro; cisplatin did so dose-dependently.
Conclusions:
- Thalidomide is not an effective single agent for this cancer model.
- Thalidomide does not provide additional benefit when combined with cisplatin.
- Cisplatin demonstrates significant antitumor activity independently.